of non-pandemic deaths globally were caused by noncommunicable diseases in WHO's 2021 estimates.
WHO · Noncommunicable diseases ↗About BioMIR
Personalized prevention.
Longitudinal intelligence.
BioMIR®—Biological Modeling for Individualized Recalibration—is a privacy-first, longitudinal bioanalytics platform built to make personal health trajectories scientifically inspectable. It connects selected biomarker signals, modeled biological-age trajectories, and recorded actions while preserving the underlying contributors and data provenance.
Background
Prevention happens between clinical snapshots.
Chronic noncommunicable diseases remain leading causes of illness, disability, and death, while many major behavioral and cardiometabolic risks remain modifiable. Modern medicine is extraordinarily capable of diagnosing and treating clinically manifest disease, but the behaviors and physiological states that shape long-term risk evolve continuously and often remain only partially observed between episodic encounters.
BioMIR began as a longitudinal N-of-1 investigation into what repeated biomarker observations can reveal between clinical encounters. Its central design question became how to select an information-dense set of signals across different biological timescales without equating more data with better inference. The founder narrative below explains the record, the scientific motivation, and how that inquiry informed the platform.
U.S. adults have at least one chronic condition; more than half have two or more.
CDC · Chronic diseases in America ↗of U.S. annual health expenditures are for people with chronic and mental health conditions.
CDC · Health and economic costs ↗Prevention framework: NIH Office of Disease Prevention · What is Prevention Research? ↗
Mission
Make prevention observable.
BioMIR’s mission is to make prevention an ongoing, interpretable, and actionable process—giving people greater visibility into their health trajectory while there is still an opportunity to influence it.
The evidence-to-action loop makes that purpose concrete: identify model-relevant biomarker contributors, consider evidence-informed behaviors, record intentions and follow-through, and examine subsequent physiological observations. Reclaimed BioAge represents eligible action-completion credit alongside the physiological models, creating a more inspectable record for individual interpretation and future research.
Vision
Build preventive health intelligence that becomes more personal over time.
BioMIR is designed as a modular and scalable scientific platform: new biomarkers, domains, and independently defined biological-age models can be evaluated without obscuring the provenance or version of existing results. Its architecture separates the calculation of a result, possible future personalization, and the interpretation presented to users.
Deterministic · current. Prespecified, version-controlled calculations produce reproducible outputs from the same eligible inputs and model version.
Adaptive · research roadmap. On-device longitudinal learning, and potentially privacy-preserving federated learning, may eventually characterize personal baselines and temporal response without silently rewriting the authoritative calculation.
Interpretive · current and future. Existing contributor views and scientific guidance explain results today; proposed AI-assisted interpretation could add a conversational interface constrained by the same underlying model and data provenance.
Adaptation and interpretation extend the scientific core; neither substitutes for a reproducible model.
Longer-term research directions
Genomic context for personalization
Genetic information can provide an individualized biological prior and help identify pathways or biomarkers that may deserve greater longitudinal attention. Genotype is context, not destiny, and does not replace measured phenotype.
Personalized biomarker panels
Future research could support configurable panels selected according to biology, risk context, longitudinal history, and evidence rather than assuming that the same expanded panel is equally informative for everyone.
Computational analytics + bioanalysis
BioMIR’s broader vision includes selective specialty bioanalysis and potential future multiplexed, customizable biosensor approaches where additional biomarkers materially improve personalization, interpretation, or longitudinal learning.
Precision-health context: NIH · All of Us Research Program ↗ · NHGRI · Genomics and Medicine ↗
Value proposition
Turn complex health data into an interpretable trajectory.
Synthesis without hiding the components.
BioMIR turns heterogeneous behavioral, functional, and cardiometabolic observations into a coherent longitudinal perspective without concealing the original biomarker contributors, dates, or model assumptions. Its value lies in a summary that can be inspected, challenged, and connected to practical follow-through—not another unexamined score.
The information-design analogy is a market index: the composite gives rapid directional orientation, while the underlying domains and biomarkers remain visible as the movers behind the trajectory. The analogy concerns aggregation and attribution—not equivalence between markets and biology.
An index with visible movers
Adaptive BioAge provides an immediately legible composite trajectory; domain and biomarker contributions explain why it moved. The headline remains decomposable rather than becoming a black box.
A quantitative in-silico assay mindset
BioMIR frames its scientific engine as a quantitative in-silico bioanalytical assay: controlled biomarker inputs, traceable data provenance, version-locked transformations, and reproducible output. Calibration, precision, linearity, specificity/selectivity, robustness, and ruggedness are explicit qualification questions for its research program. Inspect the methods.
Close the evidence-to-action loop
Scientific evidence informs biomarker selection; longitudinal models expose contributors; prioritized actions invite follow-through; and Reclaimed BioAge (REC) accounts for eligible completion credit. Subsequent biomarker observations can then be compared with that record. The loop keeps modeled credit, observed physiology, and scientific inference distinct. Explore REC and the evidence context.
Design context & further reading: S&P Dow Jones Indices · Methodology Matters ↗ · Mair et al. · Digital behavior change, PMID 37625030 ↗ · Vieira da Silva et al. · Implementation intentions and physical activity, PMID 30427874 ↗
Founder
From biotherapeutics
to prevention.
Yonathan Emmanuel is a biomedical and analytical scientist with more than two decades of experience spanning clinical diagnostics and assay development for biotherapeutics. His work centers on a recurring analytical problem: resolving meaningful biological signal from background noise arising from methodological, sampling, and temporal variability while preserving reference frameworks, provenance, and change control. Those principles became the intellectual foundation for BioMIR.
Prevention also became personal. Two hypertensive emergencies occurred against a background of known genetic risk factors, a family history of stroke and diabetes, and a demographic context associated with disproportionate cardiometabolic burden at the population level. During the COVID-19 period, disruption to routines and routine care prompted a structured N-of-1 investigation beginning in March 2021. The resulting record now spans more than 2,000 days and more than 70 variables across behavioral, dietary, restorative, aerobic-capacity, autonomic, metabolic, cardiovascular, and clinical data. A personal genomic dataset comprising more than 300,000 SNPs adds heritable context to disease-associated risk. The inquiry combined deliberate intervention, repeated observation, and reassessment.
From longitudinal inquiry to BioMIR
Within that record, a nonpharmacologic intervention coincided with sustained favorable changes in tracked cardiometabolic biomarkers. Preserved dates, provenance, and repeated observations made sustained trajectories and possible lagged associations examinable. As an N-of-1 investigation, the experience generated hypotheses rather than causal or generalizable findings.
Exploratory N-of-1 case summary
Record
- >2,000 days
- >70 variables
- March 2021 onward
Intervention context
- Nonpharmacologic intervention
- Cardiometabolic measures tracked longitudinally
Analytical value
- Timing
- Persistence
- Provenance
- Trajectories across domains
Inference boundary
- N=1 association
- Not causal evidence
- Not generalizable evidence
The inquiry informed a constrained 16-input architecture rather than importing the full record into the model. Published evidence and population references informed signal selection and reference context; a high-resolution subset supported candidate-model comparisons and provisional parameterization. The complete record is now being examined under a prespecified calibration protocol. Independent studies are needed to evaluate reliability, transportability, utility, and generalizability beyond the originating N-of-1.
BioMIR’s broader research question is whether this longitudinal framework can provide reliable, interpretable, and incrementally useful health information—and whether presenting that information as actionable feedback can support sustained preventive behavior and measurable health outcomes. BioMIR’s validation roadmap defines the independent studies required to test those questions.
Professional background, scientific collaboration, or inquiries:
Scientific documentation
Inspect the model.
Trace the evidence.
Review the public methods specification, interpretation boundaries, and supporting literature.
Company and support
Help advance the work.
Ways to engage with BioMIR beyond exploring its scientific framework and app.
Company
Investment Opportunities
Building the future of personalized prevention
Population aging and the persistent burden of chronic disease underscore the growing need for longitudinal health intelligence. By 2030, one in six people worldwide will be aged 60 or older, according to the World Health Organization.
BioMIR® is commercially available with optional Premium subscriptions. Its scientific platform combines version-controlled, on-device modeling, biomarker attribution, distinct action-linked REC accounting, and separate clinical-age comparators. The investment proposition is to expand responsible adoption while independently evaluating the framework's performance and usefulness.
Near-term priorities include product adoption, independent scientific evaluation, and strategic partnerships. Planned adaptive personalization and AI-assisted interpretation are separate research and development opportunities built around the existing reproducible core.
Our objective is to advance a scalable platform for personalized prevention, supported by documented scientific methods, independently evaluated utility, and sustainable commercial development.
We welcome discussions with investors and strategic partners interested in advancing this vision.
Company
Support BioMIR
BioMIR is independently developed. Premium subscriptions and voluntary contributions support continued software development, scientific evaluation, and accessible educational resources. If you value scientifically inspectable and privacy-conscious longitudinal health intelligence, you can help sustain the work directly.
Support BioMIR via PayPal
Choose your contribution amount. Contributions are optional and do not purchase a subscription or product access. PayPal processes your payment under its own privacy policy.
